2 results
Approved WMOPending
This study is being performed to evaluate the cognitive and psychomotor effects of the new compound LY2624803 after bedtime dosing.
Approved WMOCompleted
* Primary objective: To determine the effect of 78-weeks therapy with omalizumab compared to placebo on the number of sub-epithelial eosinophils, a marker of airway inflammation, in patients with persistent moderate to severe allergic asthma. *…